Mirodenafil

Mirodenafil

Systematic (IUPAC) name
5-Ethyl-3,5-dihydro-2-[5-([4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl)-2-propoxyphenyl]-7-propyl-4H-pyrrolo[3,2-d]pyrimidin-4-one
Clinical data
Legal status
Legal status	US: Unscheduled; not FDA approved Korea: Rx-only
Identifiers
CAS Number	862189-95-5
PubChem	CID 12001014
ChemSpider	10173481
UNII	504G362H0H
Chemical data
Formula	C26H37N5O5S
Molar mass	531.666 g/mol
SMILES CCCc1cn(CC)c2c1[nH]c(nc2=O)c1c(OCCC)ccc(c1)S(=O)(=O)N1CCN(CC1)CCO
InChI InChI=1S/C26H37N5O5S/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33) Key:MIJFNYMSCFYZNY-UHFFFAOYSA-N
(verify)

Mirodenafil belongs to a class of drugs called PDE5 inhibitors, which many other erectile dysfunction drugs such as sildenafil, tadalafil, and vardenafil also belong to. It was developed by SK Chemicals Life Science and is marketed in Korea under the trade name of Mvix tab which comes in different doses (50 mg, 100 mg).

Mirodenafil is also available under the name of Mvix S ODF 50 mg as an orally dissolving film (ODF) which dissolves on the tongue without water. It is the first licensed medicine for the treatment of erectile dysfunction as a dosage form of film.

Several clinical trials were conducted,^[1][2][3] but mirodenafil has not been approved for use in the United States by the U.S. Food and Drug Administration.

References

1. Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG (November 2008). "Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction". The Journal of Sexual Medicine 5 (11): 2672–80. doi:10.1111/j.1743-6109.2008.00945.x. PMID 18638004.
2. Kim BH, Yi S, Kim J, Lim KS, Kim KP, Lee B, Shin SG, Jang IJ, Yu KS (June 2009). "Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea". Clinical Therapeutics 31 (6): 1234–43. doi:10.1016/j.clinthera.2009.06.008. PMID 19695390.
3. Shin KH, Kim BH, Kim TE, Kim JW, Yi S, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS (December 2009). "The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study". Clinical Therapeutics 31 (12): 3009–20. doi:10.1016/j.clinthera.2009.12.012. PMID 20110038.